

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- \_\_\_\_\_ is an anti-PD-L1 antibody that was recently FDA approved for the treatment of advanced urothelial bladder cancer (UBC).
  - Atezolizumab
  - Ipilimumab
  - Pembrolizumab
  - All of the above
  - Both a and b
  - Both a and c
- The NCCN Clinical Practice Guidelines for Bladder Cancer's principles of perioperative chemotherapy indicate that it \_\_\_\_\_ acceptable to substitute carboplatin for cisplatin in the perioperative setting for patients who are not candidates for cisplatin.
  - Is
  - Is not
- On the Phase III KEYNOTE-045 trial evaluating pembrolizumab versus investigator's choice of chemotherapy for previously treated advanced UBC, which of the following groups of patients experienced the most benefit with pembrolizumab?
  - Current smokers
  - Never smokers
  - Neither a nor b
- Which of the following categories reflects the mechanism of action of durvalumab?
  - Anti-PD-L1 antibody
  - mTOR inhibitor
  - VEGF tyrosine kinase inhibitor
- Which of the following is a potential explanation for the differing results reported in the Phase III ASSURE and S-TRAC trials, which investigated adjuvant sorafenib or sunitinib versus placebo for patients with unfavorable/high-risk renal cell carcinoma (RCC)?
  - Histological presence of at least a component of clear cell disease was mandatory in S-TRAC, whereas ASSURE included patients with non-clear cell disease
  - Patients with Stage T1 and T1b tumors were included in ASSURE, whereas the S-TRAC study included only patients with Stage T3 or higher disease
  - Both a and b
- Which of the following toxicities of sunitinib appears to interfere the most with activities of daily living?
  - Diarrhea
  - Hand-foot skin reaction
  - Fatigue
- Results of the Phase III METEOR trial evaluating cabozantinib versus everolimus for patients with advanced RCC and disease progression after VEGFR tyrosine kinase inhibitor therapy demonstrated significant improvement in \_\_\_\_\_ for patients who received cabozantinib.
  - Progression-free survival
  - Overall response rate
  - Overall survival
  - All of the above
- The Phase III COMPARZ trial, which compared pazopanib to sunitinib for patients with advanced RCC, reported pazopanib to be \_\_\_\_\_.
  - Inferior
  - Noninferior
  - Superior

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

9. The combination of lenvatinib and everolimus was recently approved by the FDA for the treatment of advanced RCC after 1 prior anti-angiogenic therapy.

- a. True
- b. False

10. Common side effects of cabozantinib include \_\_\_\_\_.

- a. Diarrhea
- b. Fatigue
- c. Mucositis
- d. All of the above
- e. Both a and b
- f. Both a and c